Cargando…
The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We comp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299002/ https://www.ncbi.nlm.nih.gov/pubmed/37373615 http://dx.doi.org/10.3390/jcm12123920 |
_version_ | 1785064255665471488 |
---|---|
author | Sugita, Shurei Ogiso, Sawako Fujiwara, Masanori Morita, Euan Koyama, Takuma Hozumi, Takahiro |
author_facet | Sugita, Shurei Ogiso, Sawako Fujiwara, Masanori Morita, Euan Koyama, Takuma Hozumi, Takahiro |
author_sort | Sugita, Shurei |
collection | PubMed |
description | The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, p < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group (p = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors. |
format | Online Article Text |
id | pubmed-10299002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102990022023-06-28 The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis Sugita, Shurei Ogiso, Sawako Fujiwara, Masanori Morita, Euan Koyama, Takuma Hozumi, Takahiro J Clin Med Brief Report The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, p < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group (p = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors. MDPI 2023-06-08 /pmc/articles/PMC10299002/ /pubmed/37373615 http://dx.doi.org/10.3390/jcm12123920 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Sugita, Shurei Ogiso, Sawako Fujiwara, Masanori Morita, Euan Koyama, Takuma Hozumi, Takahiro The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title | The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title_full | The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title_fullStr | The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title_full_unstemmed | The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title_short | The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis |
title_sort | outcome of molecularly targeted therapy after surgical treatment of spinal metastasis |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299002/ https://www.ncbi.nlm.nih.gov/pubmed/37373615 http://dx.doi.org/10.3390/jcm12123920 |
work_keys_str_mv | AT sugitashurei theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT ogisosawako theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT fujiwaramasanori theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT moritaeuan theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT koyamatakuma theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT hozumitakahiro theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT sugitashurei outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT ogisosawako outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT fujiwaramasanori outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT moritaeuan outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT koyamatakuma outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis AT hozumitakahiro outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis |